Longitudinal changes in HIV-specific IFN-γ secretion in subjects who received Remune ™ vaccination prior to treatment interruption

Journal of Immune Based Therapies and Vaccines

Volumn 4, Issue , 2006, Pages

  Huang, Kenneth H ^a   Boisvert, Marie Pierre ^a   Chung, Famane ^a   Loignon, Maude ^b   Zarowny, Don ^c   Cyr, Lise ^b   Toma, Emil ^b   Bernard, Nicole F ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Canadian HIV Trials Network   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; GAG PROTEIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYDROXYUREA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN P55;

ADD ON THERAPY; ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HLA TYPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; NONHUMAN; PATIENT MONITORING; PERIPHERAL BLOOD MONONUCLEAR CELL; REBOUND; RETREATMENT; VACCINATION; VIREMIA; VIRUS IMMUNITY; VIRUS LOAD;

EID: 33845399680     PISSN: 14768518     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-4-7     Document Type: Article

References (41)

1. Palella FJ Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS: Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 1997, 94:13193-13197.
3. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD: Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997, 278:1291-1295.
4. Lucas GM, Chaisson RE, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.
5. Jain RG, Furfine ES, Pedneault L, White AJ, Lenhard JM: Metabolic complications associated with antiretroviral therapy. Antiviral Res 2001, 51:151-177.
6. Schmitz JE, Kuroda MJ, Santra S, Sasseville VG, Simon MA, Lifton MA, Racz P, Tenner-Racz K, Dalesandro M, Scallon BJ, Ghrayeb J, Forman MA, Montefiori DC, Rieber EP, Letvin NL, Reimann KA: Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
7. Borrow P, Lewicki H, Wei X, Horwitz MS, Peffer N, Meyers H, Nelson JA, Gairin JE, Hahn BH, Oldstone MB, Shaw GM: Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997, 3:205-211.
8. Goulder PJ, Phillips RE, Colbert RA, McAdam S, Ogg G, Nowak MA, Giangrande P, Luzzi G, Morgan B, Edwards A, McMichael AJ, Rowland-Jones S: Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997, 3:212-217.
9. Leslie AJ, Pfafferott KJ, Chetty P, Draenert R, Addo MM, Feeney M, Tang Y, Holmes EC, Allen T, Prado JG, Altfeld M, Brander C, Dixon C, Ramduth D, Jeena P, Thomas SA, St John A, Roach TA, Kupfer B, Luzzi G, Edwards A, Taylor G, Lyall H, Tudor-Williams G, Novelli V, Martinez-Picado J, Kiepiela P, Walker BD, Goulder PJ: HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 2004, 10:282-289.
10. Jones NA, Wei X, Flower DR, Wong M, Michor F, Saag MS, Hahn BH, Nowak MA, Shaw GM, Borrow P: Determinants of human immunodeficiency virus type I escape from the primary CD8+ cytotoxic T lymphocyte response. J Exp Med 2004, 200:1243-1256.
11. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type I syndrome. J Virol 1994, 68:4650-4655.
12. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB: Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type I infection. J Virol 1994, 68:6103-6110.
13. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, Kaslow R, Buchbinder S, Hoots K, O'Brien SJ: HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 1999, 283:1748-1752.
14. Trachtenberg E, Korber B, Sollars C, Kepler TB, Hraber PT, Hayes E, Funkhouser R, Fugate M, Theiler J, Hsu YS, Kunstman K, Wu S, Phair J, Erlich H, Wolinsky S: Advantage of rare HLA supertype in HIV disease progression. Nat Med 2003, 9:928-935.
15. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, Van Baarle D, Kostense S, Miedema F, McLaughlin M, Ehler L, Metcalf J, Liu S, Connors M: HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002, 3:1061-1068.
16. Ogg GS, Jin X, Bonhoeffer S, Moss P, Nowak MA, Monard S, Segal JP, Cao Y, Rowland-Jones SL, Hurley A, Markowitz M, Ho DD, McMichael AJ, Nixon DF: Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol 1999, 73:797-800.
17. Kalams SA, Goulder PJ, Shea AK, Jones NG, Trocha AK, Ogg GS, Walker BD: Levels of human immunodeficiency virus type I-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy. J Virol 1999, 73:6721-6728.
18. Dalod M, Dupuis M, Deschemin JC, Goujard C, Deveau C, Meyer L, Ngo N, Rouzioux C, Guillet JG, Delfraissy JF, Sinet M, Venet A: Weak anti-HIV CD8(+) T-cell effector activity in HIV primary infection. J Clin Invest 1999, 104:1431-1439.
19. Altfeld M, Rosenberg ES, Shankarappa R, Mukherjee JS, Hecht FM, Eldridge RL, Addo MM, Poon SH, Phillips MN, Robbins GK, Sax PE, Boswell S, Kahn JO, Brander C, Goulder PJ, Levy JA, Mullins JI, Walker BD: Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J Exp Med 2001, 193:169-180.
20. Alter G, Merchant A, Tsoukas CM, Rouleau D, LeBlanc RP, Cote P, Baril JG, Thomas R, Nguyen VK, Sekaly RP, Routy JP, Bernard NF: Human immunodeficiency virus (HIV)-specific effector CD8 T cell activity in patients with primary HIV Infection. J Infect Dis 2002, 185:755-765.
21. Rosenberg ES, Altfeld M, Poon SH, Phillips MN, Wilkes BM, Eldridge RL, Robbins GK, D'Aquila RT, Goulder PJ, Walker BD: Immune control of HIV-1 after early treatment of acute infection. Nature 2000, 407:523-526.
22. Oxenius A, Price DA, Gunthard HF, Dawson SJ, Fagard C, Perrin L, Fischer M, Weber R, Plana M, Garcia F, Hirschel B, McLean A, Phillips RE: Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A 2002, 99:13747-13752.
23. Oxenius A, McLean AR, Fischer M, Price DA, Dawson SJ, Hafner R, Schneider C, Joller H, Hirschel B, Phillips RE, Weber R, Gunthard HF: Human immunodeficiency virus-specific CD8(+) T-cell responses do not predict viral growth and clearance rates during structured intermittent antiretroviral therapy. J Virol 2002, 76:10169-10176.
24. Oxenius A, Hirschel B: Structured treatment interruptions in HIV infection: benefit or disappointment? Expert Rev Anti Infect Ther 2003, 1:129-139.
25. Turner JL, Kostman JR, Aquino A, Wright D, Szabo S, Bidwell R, Goodgame J, Daigle A, Kelley E, Jensen F, Duffy C, Carlo D, Moss RB: The effects of an HIV-1 immunogen (Remune) on viral load, CD4 cell counts and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med 2001, 2:68-77.
26. Moss RB, Giermakowska WK, Wallace MR, Savary JR, Jensen FC, Carlo DJ: Cell-mediated immune responses to autologous virus in HIV-1-seropositive individuals after treatment with an HIV-1 immunogen. AIDS 2000, 14:2475-2478.
27. Moss RB, Brandt C, Giermakowska WK, Savary JR, Theofan G, Zanetti M, Carlo DJ, Wallace MR: HIV-specific immunity during structured antiviral drug treatment interruption. Vaccine 2003, 21:1066-1071.
28. Fernandez-Cruz E, Moreno S, Navarro J, Clotet B, Bouza E, Carbone J, Pena JM, Perez MJ, Podzamczer D, Rubio R, Ocana I, Pulido F, Viciana P, Maradona JA, Blazquez R, Barros C, Quereda C, Rodriguez-Sainz C, Gil J, Abad ML, Diaz L, Canto C, Munoz MA, Ferrer E, Jou A, Sirera G, Diaz M, Lopez F, Gatell JM, Gonzalez-Lahoz J: Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects. Vaccine 2004, 22:2966-2973.
29. Bunce M, O'Neill CM, Barnardo MC, Krausa P, Browning MJ, Morris PJ, Welsh KI: Phototyping: comprehensive DNA typing for HLA-A, B, C, DRB1, DRB3, DRB4, DRB5 & DQB1 by PCR with 144 primer mixes utilizing sequence-specific primers (PCR-SSP). Tissue Antigens 1995, 46:355-367.
30. Brander C, Goulder PJR: Recent advances in the optimization of HIV-specific CTL epitopes. In HIV Molecular Immunology Database Los Alamos, New Mexico, USA: Los Alamos National Laboratory: Theoretical Biology and Biophysics; 1999.
31. Alter G, Hatzakis G, Tsoukas CM, Pelley K, Rouleau D, LeBlanc R, Baril JG, Dion H, Lefebvre E, Thomas R, Cote P, Lapointe N, Routy JP, Sekaly RP, Conway B, Bernard NF: Longitudinal assessment of changes in HIV-specific effector activity in HIV-infected patients starting highly active antiretroviral therapy in primary infection. J Immunol 2003, 171:477-488.
32. Altfeld M, Addo MM, Shankarappa R, Lee PK, Allen TM, Yu XG, Rathod A, Harlow J, O'Sullivan K, Johnston MN, Goulder PJ, Mullins JI, Rosenberg ES, Brander C, Korber B, Walker BD: Enhanced detection of human immunodeficiency virus type I-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol 2003, 77:7330-7340.
33. Horton H, Russell N, Moore E, Frank I, Baydo R, Havenar-Daughton C, Lee D, Deers M, Hudgens M, Weinhold K, McElrath MJ: Correlation between interferon-gamma secretion and cytotoxicity, in virus-specific memory T cells. J Infect Dis 2004, 190:1692-1696.
34. Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, Roederer M, Koup RA: Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003, 281:65-78.
35. Betts MR, Koup RA: Detection of T-cell degranulation: CD107a and b. Methods Cell Biol 2004, 75:497-512.
36. Wherry EJ, Ahmed R: Memory CD8 T-cell differentiation during viral infection. J Virol 2004, 78:5535-5545.
37. Addo MM, Yu XG, Pathod A, Cohen D, Eldridge RL, Strick D, Johnston MN, Corcoran C, Wurcel AG, Fitzpatrick CA, Feeney ME, Rodriguez WR, Basgoz N, Draenert R, Stone DR, Brander C, Goulder PJ, Rosenberg ES, Altfeld M, Walker BD: Comprehensive epitope analysis of human immunodeficiency virus type I (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J Virol 2003, 77:2081-2092.
38. Peretz Y, Alter G, Boisvert MP, Hatzakis G, Tsoukas CM, Bernard NF: Human immunodeficiency virus (HIV)-specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline. J Virol 2005, 79:4908-4917.
39. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, Lederman MM, Benito JM, Goepfert PA, Connors M, Roederer M, Koup RA: HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
40. Younes SA, Yassine-Diab B, Dumont AR, Boulassel MR, Grossman Z, Routy JP, Sekaly RP: HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003, 198:1909-1922.
41. Valor L, Navarro J, Santamaria B, Rodriguez-Sainz C, Carbone J, Gil J, Podzamczer D, González Lahoz J, Viciana P, Ocaña I, Clotet B, Rubio R, Pulido F, Moreno S, Maradona J, Quereda C, Blazquez R, Ferrer E, Díaz M, Jou A, Sirera G, Peña J, Gijón P, Gatell J, López F, Desco M, Fernandez-Cruz E: Therapeutic vaccination with Remune induces polyfunctional CD8+ HIV-1 specific T cell responses in HIV-1 chronic infection. XVI International AIDS Conference 2006, Abstract no.:TUPE0034.